Arrivent Biopharma Inc (AVBP)

2026-08-17T10:20:18.000Z - 2 days ago

ArriVent Biopharma price target raised to $47 from $44 at H.C. Wainwright

2026-08-17T08:17:10.000Z - 2 days ago

ArriVent Biopharma price target lowered to $40 from $43 at Citi

Aug 12, 2026, 4:01 PM EDT - 6 days ago

ArriVent BioPharma Reports Second Quarter 2026 Financial Results

Aug 12, 2026, 4:00 PM EDT - 6 days ago

ArriVent BioPharma Earnings release: Q2 2026

Aug 12, 2026, 4:00 PM EDT - 6 days ago

ArriVent BioPharma Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 7 days ago

ArriVent BioPharma Slides: Corporate presentation

Jun 18, 2026, 12:00 PM EDT - 2 months ago

ArriVent BioPharma Transcript: AGM 2026

2026-05-29T14:49:43.000Z - 2 months ago

ArriVent Biopharma assumed with a Buy at Truist

2026-05-13T10:44:40.000Z - 3 months ago

ArriVent Biopharma price target lowered to $43 from $45 at Citi

2026-05-11T21:38:55.000Z - 3 months ago

ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)

May 11, 2026, 4:01 PM EDT - 3 months ago

ArriVent BioPharma Reports First Quarter 2026 Financial Results

May 11, 2026, 4:00 PM EDT - 3 months ago

ArriVent BioPharma Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

ArriVent BioPharma Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

ArriVent BioPharma Slides: Corporate presentation

2026-05-07T18:45:02.000Z - 3 months ago

ArriVent Biopharma announces FDA clearance of ARR-002 NDA

May 7, 2026, 8:00 AM EDT - 3 months ago

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Apr 28, 2026, 8:00 AM EDT - 4 months ago

ArriVent BioPharma Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

ArriVent BioPharma Proxy statement: Proxy filing

2026-04-24T11:06:33.000Z - 4 months ago

Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’

2026-03-23T12:51:34.000Z - 5 months ago

ArriVent Biopharma price target raised to $45 from $37 at B. Riley

Mar 17, 2026, 5:00 PM EDT - 5 months ago

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

2026-03-11T20:28:14.000Z - 5 months ago

ArriVent Biopharma assumed with a Buy at BTIG

2026-03-06T12:53:00.000Z - 5 months ago

ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer

2026-03-06T11:15:50.000Z - 5 months ago

ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright

2026-03-06T11:00:30.000Z - 5 months ago

ArriVent Biopharma price target raised to $33 from $31 at Citi

Mar 5, 2026, 4:01 PM EST - 5 months ago

ArriVent BioPharma Reports Full Year 2025 Financial Results

Mar 5, 2026, 9:30 AM EST - 5 months ago

ArriVent BioPharma Annual report: Q4 2025

Mar 5, 2026, 9:30 AM EST - 5 months ago

ArriVent BioPharma Earnings release: Q4 2025

2026-02-17T15:25:37.000Z - 6 months ago

Omega takes new stake in Rocket Companies, exits ArriVent Biopharma

ABR AESI APO DMAC ET GEHC MANU

2025-12-22T21:20:44.000Z - 8 months ago

ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald

2025-12-22T13:06:00.000Z - 8 months ago

ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study

Dec 22, 2025, 8:00 AM EST - 8 months ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

2025-12-10T11:46:01.000Z - 9 months ago

ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential

2025-12-10T11:40:54.000Z - 9 months ago

ArriVent Biopharma initiated with a Buy at BTIG

2025-11-25T11:25:25.000Z - 9 months ago

ArriVent Biopharma initiated with a Buy at Truist

Nov 10, 2025, 8:00 AM EST - 10 months ago

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 10 months ago

ArriVent BioPharma Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

ArriVent BioPharma Quarterly report: Q3 2025

Sep 22, 2025, 4:05 PM EDT - 11 months ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Sep 9, 2025, 8:00 AM EDT - 1 year ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Aug 11, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Earnings release: Q2 2025

Jul 21, 2025, 8:00 AM EDT - 1 year ago

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Jul 1, 2025, 11:15 PM EDT - 1 year ago

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 4:05 PM EDT - 1 year ago

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jun 23, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Press release: Study Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Slides: Study Update

Jun 23, 2025, 7:00 AM EDT - 1 year ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Jun 20, 2025, 4:05 PM EDT - 1 year ago

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Quarterly report: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Proxy statement: Proxy Filing

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Reports Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Earnings release: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Annual report: Q4 2024

Jan 21, 2025, 7:00 PM EST - 1 year ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Nov 14, 2024, 8:00 AM EST - 1 year ago

ArriVent BioPharma Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

ArriVent BioPharma Earnings release: Q3 2024

Sep 9, 2024, 12:05 PM EDT - 2 years ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aug 15, 2024, 7:01 AM EDT - 2 years ago

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 14, 2024, 4:01 PM EDT - 2 years ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:00 PM EDT - 2 years ago

ArriVent BioPharma Quarterly report: Q2 2024

Aug 14, 2024, 4:00 PM EDT - 2 years ago

ArriVent BioPharma Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Jun 5, 2024, 7:00 AM EDT - 2 years ago

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

May 16, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 8, 2024, 8:00 AM EDT - 2 years ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 2 years ago

ArriVent BioPharma Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

ArriVent BioPharma Earnings release: Q1 2024

Apr 22, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints Kristine Peterson to its Board of Directors

Mar 28, 2024, 8:30 PM EDT - 2 years ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ArriVent BioPharma Reports Full Year 2023 Financial Results